Moberg Pharma AB (publ)
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.
Moberg Pharma AB (publ) (MOB) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.012x
Based on the latest financial reports, Moberg Pharma AB (publ) (MOB) has a cash flow conversion efficiency ratio of -0.012x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-8.26 Million) by net assets (Skr676.90 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Moberg Pharma AB (publ) - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how Moberg Pharma AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Moberg Pharma AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Moberg Pharma AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tethys Petroleum Limited
PINK:TETHF
|
0.069x |
|
Mitre Realty Empreendimentos e Participações S.A
SA:MTRE3
|
0.044x |
|
Broadway Financial Corporation
NASDAQ:BYFC
|
0.015x |
|
Peoplein Ltd
AU:PPE
|
0.082x |
|
Navitas Petroleum Limited Partnership
TA:NVPT
|
0.032x |
|
GetNinjas S.A
SA:NINJ3
|
0.022x |
|
Otsuka Information Technology Corp.
TWO:3570
|
0.073x |
|
Sindhu Trade Links Limited
NSE:SINDHUTRAD
|
0.013x |
Annual Cash Flow Conversion Efficiency for Moberg Pharma AB (publ) (2008–2024)
The table below shows the annual cash flow conversion efficiency of Moberg Pharma AB (publ) from 2008 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr686.82 Million | Skr-16.47 Million | -0.024x | +55.89% |
| 2023-12-31 | Skr610.73 Million | Skr-33.20 Million | -0.054x | -72.25% |
| 2022-12-31 | Skr533.58 Million | Skr-16.84 Million | -0.032x | +10.43% |
| 2021-12-31 | Skr434.05 Million | Skr-15.30 Million | -0.035x | +53.42% |
| 2020-12-31 | Skr395.58 Million | Skr-29.93 Million | -0.076x | -302.29% |
| 2019-12-31 | Skr105.68 Million | Skr3.95 Million | 0.037x | -69.94% |
| 2018-12-31 | Skr594.02 Million | Skr73.89 Million | 0.124x | +27.68% |
| 2017-12-31 | Skr552.41 Million | Skr53.82 Million | 0.097x | +404.98% |
| 2016-12-31 | Skr561.62 Million | Skr-17.94 Million | -0.032x | -136.69% |
| 2015-12-31 | Skr352.82 Million | Skr30.72 Million | 0.087x | +63.63% |
| 2014-12-31 | Skr303.75 Million | Skr16.16 Million | 0.053x | +440.35% |
| 2013-12-31 | Skr201.49 Million | Skr-3.15 Million | -0.016x | -129.40% |
| 2012-12-31 | Skr178.23 Million | Skr9.48 Million | 0.053x | +145.26% |
| 2011-12-31 | Skr76.79 Million | Skr-9.02 Million | -0.117x | +99.73% |
| 2010-12-31 | Skr687.70K | Skr-30.41 Million | -44.224x | -5189.34% |
| 2009-12-31 | Skr30.21 Million | Skr-25.26 Million | -0.836x | +63.51% |
| 2008-12-31 | Skr15.23 Million | Skr-34.89 Million | -2.291x | -- |